CNS - Cohen & Steers, Inc.
NEW YORK, May 21, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced that Amit Muni has been appointed as Executive Vice President and Chief Financial Officer, effective June 8, 2026. Mr. Muni will lead the firm's financial operations, financial strategy and investor relations.
Cohen and Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
NEW YORK, May 20, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS), today announced it is partnering with J.P. Morgan to provide access to the Cohen & Steers SICAV Short Duration Hybrid Credit & Income Fund for investors outside the United States across J.P.
/PRNewswire/ -- Cohen and Steers, Inc. (NYSE: CNS), today announced it is partnering with J.P. Morgan to provide access to the Cohen and Steers SICAV Short
Access the CEO Connect segment here HOUSTON, TX / ACCESS Newswire / May 20, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor CEO Connect Segment. As part of the segment, Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.
CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin glioblastoma story.
Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy Company actively evaluating multiple acquisition opportunities while advancing discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287 New executive leadership team assembled in the first quarter continues to demonstrate rapid execution against strategy HOUSTON, TX / ACCESS Newswire / May 14, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting the Company's ongoing strategic transformation and execution progress. The first quarter of 2026 marked the beginning of a significant strategic shift for CNS Pharmaceuticals, including the appointment of a new Chief Executive Officer and executive leadership team, the launch of a new corporate strategy, the repositioning of the Company toward an acquisition-driven growth strategy focused on differentiated clinical-stage assets in neurology and oncology and the decision to seek out-licensing opportunities for its legacy glioblastoma multiforme programs, Berubicin and TPI-287.
NEW YORK, May 13, 2026 /PRNewswire/ -- Cohen & Steers Income Opportunities REIT, Inc. ("CNSREIT") announced its latest acquisition, a high-quality community shopping center in Charlotte, N.C. The investment was made through a programmatic joint venture with Sterling Organization, a real estate investment firm that specializes in shopping centers in the U.S. Winslow Bay Commons is a 268,000 square foot shopping center located in Mooresville, N.C.
NEW YORK, May 11, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $100.1 billion as of April 30, 2026, an increase of $7.0 billion from assets under management of $93.1 billion at March 31, 2026. The increase was due to market appreciation of $6.4 billion and net inflows of $701 million, partially offset by distributions of $152 million.
NEW YORK, May 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on May 15, 2026. Cohen & Steers Global Realty Majors Portfolio Index (GRM) Added component (symbol) Removed component (symbol) Azrieli Group Ltd.
Plenary session at AANS underscores REYOBIQ's potential as a differentiated targeted radiotherapeutic platform for CNS cancers Plenary session at AANS underscores REYOBIQ's potential as a differentiated targeted radiotherapeutic platform for CNS cancers
CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Wednesday's premarket session.
AGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a late-stage clinical biopharmaceutical company focused on oncology and rare diseases, today announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc. (“LNAI”) for its N2B (nose-to-brain) delivery system, establishing an initiative on biodefense and Alzheimer's disease (AD). In return, Oncotelic received $12.5 million in Lunai Bioworks Series B Convertible Preferred Stock. The Company continues to evaluate additional partnerships to further monetize its portfolio while maintaining strategic control over core assets.
Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505(b)(2) Pathways, and CNS Countermeasure Applications SACRAMENTO, Calif., May 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced the completion of a $20 million preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the Company's central nervous system (CNS) platform with complementary neurotherapeutic compounds and delivery technologies.
CNS Pharmaceuticals Inc. (NASDAQ:CNSP) shares are up during Monday's premarket session following the announcement of an oversubscribed private placement financing expected to generate approximately $22.5 million.
The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy HOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5 million to the Company, before placement agent fees and offering expenses. The private placement includes participation from institutional healthcare investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners.
NEW YORK, April 30, 2026 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the second quarter of 2026 in the amount of $0.67 per share of common stock payable on May 21, 2026 to stockholders of record as of the close of business on May 11, 2026. About Cohen & Steers.
/PRNewswire/ -- Cohen and Steers, Inc. (NYSE: CNS) a annoncé aujourd'hui qu'elle avait changé le nom de deux de ses fonds SICAV afin de mieux refléter les
/PRNewswire/ -- Cohen and Steers, Inc. (NYSE: CNS) announced today that it has changed the name of two of its SICAV funds to better align with market definitions
NEW YORK, April 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of the distribution to be paid on April 30, 2026 and cumulative distributions paid fiscal year-to-date. In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.